Well-designed clinical trials are essential for healthcare innovation as they provide reliable, high-quality evidence on the comparative effectiveness and safety of new interventions. Due to increased complexity of today’s healthcare challenges, innovative methods are needed to increase the efficiency and feasibility of clinical trials and accelerate healthcare innovation.
For enquiries about collaborations and support, contact Peter van de Ven.
We are a team of biostatisticians and epidemiologists who focus on the design and analysis of both traditional and innovative clinical trials. We actively collaborate with clinical researchers and other stakeholders to ensure that clinical trials remain feasible while providing the highest quality evidence, with the goal of improving patient outcomes. We are represented in institutional review boards, grant review committees and have members seconded as methodology assessors at the Dutch Medicines Evaluation Board (CBG-MEB).
Our expertise covers many innovative trial methodologies for both early-phase and confirmatory trials. This includes (Bayesian) adaptive trials, adaptive early-phase dose-finding trials, platform trials, basket trials, trials-within-cohort (TwiCs) studies, cross-over trials, N-of-1 trials, stepped-wedge trials, trials with decentralized elements, and trials where external trial or real-world data is leveraged in the statistical analysis.